This mini case study review article is the third in a series exploring tumour necrosis factor (TNF) inhibitors in the treatment of immune-mediated disease. This article explores anti-TNF therapies, which are generally considered to be an effective, well-tolerated treatment option for the management of chronic conditions related to the overproduction of TNF-α.
EMJ Gastroenterology 11 [Supplement 7] . 2022
Latest articlesAll articles
Let’s Start at the Beginning: A Healthy Gut From Day 1
Establishing healthy nutrition practices from infancy through to childhood and adolescence is essential in ensuring a healthy digestive system throughout our lives. Several studies have found that changes made during these early years can have a significantly positive effect later in life, including the prevention of non-communicable diseases, such as obesity, diabetes, inflammatory diseases, and certain types of cancer.
Severe, Refractory Anaemia Associated with Helicobacter Pylori Infection Managed With L. Reuteri DSMZ17648 (Probiotic) and Haeme Iron Supplements: A Case Report
Iron deficiency anaemia (IDA) is a global health problem affecting both developing and developed countries, particularly in Asia. Nutritional deficiency, menstrual blood loss, and chronic gastrointestinal blood loss are the common causes of IDA.
A Rare Complication of Valproate-Induced Acute Pancreatitis in an Adult Patient with Bipolar Disorder: A Case Report
Sodium valproate, or valproic acid (VPA), is a broad-spectrum antiepileptic drug, commonly used for the treatment of epilepsy, bipolar disorder, migraine headache, and diabetic-neuropathy related pain. VPA was approved by the U.S. Food and Drug Administration (FDA) in 1978 for treating epilepsy and absence seizures.
Anti-TNF Treatment in Crohn’s Disease Complicated by Intra-abdominal Abscess
Excess production of TNF-α leads to chronic inflammation and tissue damage in immune-mediated inflammatory diseases (IMID) such as Crohn’s Disease (CD), rheumatoid arthritis, and psoriasis. The introduction of anti-TNF agents revolutionised therapy for patients with IMIDs, and two anti-TNFs are currently approved for use in CD in Europe: infliximab and adalimumab.